A paper trail buried in routine federal disclosures has thrust Rep. Alexandria Ocasio-Cortez into an unexpected spotlight this week.
Buried within campaign finance records lies a series of payments connecting her political operation to a physician whose specialty has become synonymous with both cutting-edge psychiatric treatment and Hollywood tragedy.
Three transactions, spread across March, May and October of last year, sent a combined $18,725 from Ocasio-Cortez’s campaign coffers to Dr. Brian Boyle.
The largest single payment, $11,550, landed in March. Smaller sums of $2,800 and $4,375 followed in the months after.
Boyle isn’t just any physician. He holds the title of chief psychiatric officer at Stella, a chain of mental health clinics that has built part of its reputation around ketamine-based treatment protocols.
His credentials trace back to Harvard, and he markets himself professionally as an “interventional psychiatrist” who treats stubborn cases of depression, PTSD and anxiety that haven’t responded to conventional therapy.
Curiously, none of the three payments appear in campaign filings under any medical or psychiatric category.
Instead, bookkeepers labeled the expenditures “leadership training and consulting” — a description that leaves plenty of room for interpretation.
That ambiguity is doing a lot of work.
Nothing in the public record proves Ocasio-Cortez herself sat across from Boyle for a psychiatric session, let alone received ketamine therapy directly.
The filings establish only that her campaign wrote the checks and attached that particular label to them.
Reporters at the New York Post pressed for answers about what actually transpired during these sessions, who was involved, and what “leadership training and consulting” was meant to describe.
The campaign offered no response.
Boyle’s own marketing materials lean into his ketamine expertise, describing him as one of the field’s foremost authorities.
Ketamine itself occupies a strange dual identity in modern medicine — approved and widely used as a surgical anesthetic, while also gaining traction in recent years as an off-label psychiatric treatment administered under clinical supervision.
That same drug carries baggage.
Its potential for abuse has made it a subject of ongoing concern among regulators, and its public profile shifted dramatically after October 2023, when actor Matthew Perry died from what investigators determined were the acute effects of ketamine use.
The fallout from Perry’s death led to criminal charges against multiple individuals accused of illegally providing him with the drug.
Boyle addressed his career path during a podcast appearance last year, describing what drew him toward this niche corner of psychiatry.
“I just saw the incredible power of what these treatments could do,” he said, per the Post’s account of the interview.
He didn’t stop there. “It’s a ton of fun helping patients get better,” Boyle added, describing his enthusiasm for the work.
Ketamine represents only one offering at Stella’s network of clinics.
The practice also provides stellate ganglion block, a procedure that has found favor among wealthy and famous patients seeking alternatives to traditional treatment.
The technique involves injecting anesthetic near a bundle of nerves in the neck, targeting the body’s sympathetic nervous system in hopes of easing PTSD symptoms.
Among those who’ve championed the procedure publicly is Bob Parsons, the billionaire who founded GoDaddy.
A Vietnam veteran, Parsons has spoken candidly for years about his personal battle with PTSD.
Boyle, reflecting on why celebrities gravitate toward his clinic’s offerings, offered this assessment in a past interview:
“Celebrities tend to be more inclined to be on the hunt for highly effective solutions across beauty, health, mental health, nutrition and so on.”
The revelations about Boyle’s payments don’t exist in a vacuum.
They arrive alongside a well-documented legislative record showing Ocasio-Cortez has spent years pushing to loosen federal restrictions surrounding psychedelic drug research.
Her history on drug policy dates back to her 2018 congressional campaign, when she ran on ending federal marijuana prohibition.
Since arriving in Washington, she has introduced multiple bills aimed at clearing regulatory hurdles for scientists studying substances like psilocybin and MDMA.
One of her earliest legislative efforts, introduced during her freshman year in 2019, sought to strip away barriers blocking federal funds from supporting research into Schedule I substances’ potential medical applications — specifically targeting psilocybin, the compound found in “magic mushrooms,” and MDMA.
At the time, Ocasio-Cortez called early psychedelic research “promising” and insisted federal law shouldn’t obstruct scientists from investigating the substances’ therapeutic potential.
Whether the newly surfaced payments connect to that broader policy interest remains an open question — one campaign officials have so far declined to answer.
